Survey Report on Complaints Related to the Interconnectivity between Vial Containers and Transfer Devices

References

1. 1.↵
   1. Massoomi F.

   The Evolution of the CSTD. Pharmacy Purchasing & Products, February 2015, S1–S12.
2. 2.↵
   NIOSH. NIOSH Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings; DHHS (NIOSH) Publication No. 2004-165; U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health: Cincinnati, OH, 2004.
3. 3.↵
   European Agency for Safety and Health at Work. Directive 2010/32/EU: Prevention from Sharp Injuries in the Hospital and Healthcare Sector. EU-OSHA, 2010.
4. 4.↵
   U.S. Pharmacopeial Convention, General Chapter <800> Hazardous Drugs—Handling in Healthcare Settings. USP Web site. http://www.usp.org/usp-healthcare-professionals/compounding/compounding-general-chapters/usp-general-chapter-hazardous-drugs-handling-healthcare-se. Ac-cessed July 19, 2019.
5. 5.↵
   1. Elseviers M. M.,
   2. Arias-Guillen M.,
   3. Gorke A.,
   4. Arens H.-J.

   Sharps Injuries Amongst Healthcare Workers: Review of Incidence, Transmissions and Costs. J. Ren. Care 2014, 40 (3), 150–156.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Dolan S. A.,
   2. Arias K. M.,
   3. Felizardo G.,
   4. Barnes S.,
   5. Kraska S.,
   6. Patrick M.,
   7. Bumsted A.

   APIC Position Paper: Safe Injection, Infusion, and Medication Vial Practices in Health Care. Am. J. Infect. Control 2016, 44 (7), 750–757.

   OpenUrl
7. 7.↵
   1. Zhao X. C.,
   2. Ho L.,
   3. Bantz D.,
   4. Hostetler D.,
   5. Fang L.

   A Case Study to Address a Gap in the Device-to-Vial Interface Stopper Push-in by Chemo Spikes. PDA J. Pharm. Sci. Technol. 2019, 73 (1), 92–109.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Zhao C.,
   2. Radwick A.

   5 Challenges of Closed System Transfer Devices - New USP Chapter Specifies Use of Closed System Transfer Devices for Hazardous Drugs Spurring Industry Response. PDA Letter January/February 2020, 42–48.
9. 9.↵
   1. Budhavaram N.,
   2. et al

   . Development of Guidance for the Interconnect-ability between Vial Container Closure Systems and Vial Transfer Devices. Presented at SPE MiniTec, Anaheim, CA, February 2019.
10. 10.↵
    1. Budhavaram N.,
    2. Zhao C.

    Development of Guidance for the Interconnectibility between Vial Container Closure Systems and Vial Transfer Devices. Presented at 2020 PDA Europe Conference: Parenteral Packaging, Basel, Switzerland, February 2526, 2020.
11. 11.↵
    1. Besheer A.,
    2. Mahler H.-C.,
    3. Matter-Schwald A.,
    4. Barrenechea S. M.,
    5. Vogt M.,
    6. Chalus P.,
    7. Heymes P.,
    8. Pillow T.,
    9. Kirste A.,
    10. Favrod P.,
    11. Joerg S.,
    12. Mathaes R.

    Evaluation of Different Quality-Relevant Aspects of Closed System Transfer Devices (CSTDs). Pharm. Res. 2020, 37 (4), 81.

    OpenUrl
12. 12.↵
    1. Sreedhara A.,
    2. Zamiri C.,
    3. Goswami S.,
    4. Weiser S.,
    5. Cram M.,
    6. Christian T. R.,
    7. Jagannathan B.

    Challenges of Using Closed System Transfer Devices with Biological Drug Products: An Industry Perspective. J. Pharm. Sci. 2020, 109 (1), 22–29.

    OpenUrl
13. 13.↵
    1. Petoskey F.,
    2. Kwok S.,
    3. Jackson W.,
    4. Jiang S.

    Overcoming Challenges of Implementing Closed System Transfer Device Clinical in-Use Compatibility Testing for Drug Development of Antibody Drug Conjugates. J. Pharm. Sci. 2020, 109 (1), 761–768.

    OpenUrl